Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study.

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Lenvima (lenvatinib) - Eisai, Merck (MSD)

Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study. (PubMed, J Hepatocell Carcinoma) - Sep 9, 2026 - "Grade ≥3 TEAEs were observed in 17.3% of patients. First-line nivolumab plus lenvatinib and intra-arterial locoregional therapy showed encouraging antitumor activity and a manageable safety profile in unresectable HCC."
Journal • Real-world evidence • Fatigue • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42707588

Bin Huang; Guowen Li; Haixiong Yan; Manping Huang; Muzi Li; Shanzhi Gu; Yang Zhao; Zhengping Xiong

Sep 9, 2026